Ceftriaxone

FDA

• Lower respiratory tract infections
  • S. pneumoniae, S. aureus, H. influenzae,Haemophilus parainfluenzae, K. pneumoniae, E. coli, Klebsiella aerogenes (formerly Enterobacter aerogenes), P. mirabilis, or Serratia marcescens.
• Acute bacterial otitis media
  • S. pneumoniae
  • Beta-lactamase-producing strains
    • Haemophilus influenzae
    • Moraxella catarrhalis
• Skin and skin structure infections
• Urinary tract infections (complicated and uncomplicated)
• Uncomplicated gonorrhea
• Pelvic inflammatory disease
• Bacterial septicemia
  • Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae, or Klebsiella pneumoniae.
• Bone and joint infections
  • S. aureus, S. pneumoniae, E. coli, Proteus mirabilis, K. pneumoniae, or Enterobacter spp.
• Intra-abdominal infections
• Meningitis
  • H. influenzae, Neisseria meningitidis, or S. pneumoniae.
• Surgical prophylaxis

NON-FDA APPROVED USES

Incomplete list

• Actinomycosis
• Brain abscess (with metronidazole)
• Appendicitis (with metronidazole)
• Peritonitis: spontaneous bacterial and secondary
• Endocarditis
• Diabetic foot infections (with metronidazole or clindamycin)
• Lyme disease, late Lyme arthritis
• Meningococcal meningitis prophylaxis: 125 mg x1 (< 15 yrs); 250 mg x1 (≥15 yrs)
• Neurosyphilis
• Disseminated GC